Myasthenia Gravis Awareness Month and the Role of Treatment Options
June is Myasthenia Gravis (MG) Awareness Month, a time to raise awareness about this rare and often misunderstood neuromuscular disorder. MG affects the communication between nerves and muscles, leading to weakness in voluntary muscles. This month, we focus on the challenges of living with MG, the importance of early diagnosis, and the transformative role that treatment options like Rystiggo, Soliris, Ultomiris, Vyvgart, and Vyvgart Hytrulo play in
managing this debilitating condition.
Understanding Myasthenia Gravis (MG)
Myasthenia Gravis is an autoimmune disorder where the body’s immune system mistakenly attacks the communication between nerves and muscles. Normally, nerve impulses stimulate muscle contractions, allowing for voluntary movement. However, in MG, antibodies block or destroy the acetylcholine receptors at the neuromuscular junction, the point where nerves connect to muscles. This interruption weakens the muscles, often starting with the eyes, face, and throat, and can progress to other muscle groups, leading to difficulty with swallowing, speaking, breathing, and performing daily tasks. While MG can affect anyone, it is often diagnosed in adults, particularly women under 40 and men over 60. The disorder can range from mild to severe, with symptoms fluctuating throughout the day. Because of the variability in symptoms, MG can be difficult to diagnose, which is why awareness campaigns like the one in June are crucial to highlight the disease’s signs, symptoms, and available treatments.
The Role of Medications in MG Treatment
Although there is no cure for MG, several medications are used to manage symptoms, reduce the immune response, and improve muscle strength. Treatment aims to improve quality of life, prevent exacerbations, and, in some cases, prevent permanent damage. Five groundbreaking treatments are offered at Sage Infusion and have shown great promise in treating MG: Rystiggo, Soliris, Ultomiris, Vyvgart, and Vyvgart Hytrulo.
Rystiggo (Rozanolixizumab-noli)
Rystiggo, a newer addition to the arsenal of MG treatments, is a subcutaneous (sub-Q) infusion therapy designed to target the autoimmune process that contributes to the disease. It targets neonatal Fc receptors (FcRn) to reduce harmful IgG antibodies attacking the neuromuscular junction. It offers a faster-acting option for patients who don’t respond well to conventional
MG therapies.
Soliris (Eculizumab)
Initially approved for other autoimmune conditions, Soliris now treats generalized MG by inhibiting the complement system, which plays a role in autoimmune attacks. Soliris targets the C5 protein, reducing inflammation and providing relief for severe cases. Because of its immunomodulatory properties, Soliris can be a game-changer for patients with severe MG who require more aggressive treatments. Its ability to provide relief for difficult-to-treat cases has made it an essential medication for some MG patients.
Ultomiris (Ravulizumab)
Ultomiris is similar to Soliris in that it is approved for the treatment of generalized MG in patients who have not responded to first-line therapies and also targets the C5 complement protein, but it has a longer half-life, meaning it can be administered less frequently. This is a significant advantage for patients who require regular infusions. Ultomiris was developed to provide similar benefits as Soliris but with a more convenient dosing schedule, usually once every eight weeks. This extended dosing interval is especially beneficial for those with busy lifestyles or for those who experience difficulty tolerating frequent infusions.
Vyvgart (Efgartigimod)
Vyvgart represents a shift in treatment options, as it is the first approved therapy that targets the neonatal Fc receptor (FcRn) in a different way than Rystiggo. Vyvgart is an intravenous infusion that lowers pathogenic IgG antibodies by inhibiting FcRn, helping to restore muscle strength. Approved for adult MG patients with positive acetylcholine receptor antibodies, Vyvgart offers a new treatment avenue for those unresponsive to traditional therapies.
Vyvgart Hytrulo (Efgartigimod Hyaluronidase)
Vyvgart Hytrulo is an updated version of Vyvgart, formulated with hyaluronidase to facilitate subcutaneous (under the skin) administration. It allows for a rapid sub-Q infusion, administered in just 30 to 90 seconds. It provides the same benefits as Vyvgart while reducing infusion time and increasing patient flexibility.
A Bright Future for MG Treatment
As we observe MG Awareness Month this June, it is essential to celebrate the progress made in both the awareness of the disease and the treatment options available to patients. The introduction of drugs like Rystiggo, Soliris, Ultomiris, Vyvgart, and Vyvgart Hytrulo has provided patients with new hope and opportunities for improved quality of life. These treatments, each targeting the autoimmune mechanisms in distinct ways, offer patients flexibility in managing their symptoms and achieving better control over their disease.
In addition to medical advancements, the ongoing effort to raise awareness, fund research, and provide support to those affected by MG is crucial. For the thousands of individuals living with this chronic condition, these treatments represent more than just medications—they are lifelines that empower them to live fuller, more independent lives.
As we continue to advocate for better treatments, early diagnosis, and greater public awareness, let’s make this June a time to reflect on the challenges of living with Myasthenia Gravis and the incredible progress that has been made toward improving the lives of those affected.
Sage Infusion Can Help
Sage Infusion provides expert patient-centered infusion care in a contemporary boutique environment. We offer infusion treatments to patients and will coordinate care with the referring physician, including insurance authorization and patient progress updates. Our flexible scheduling meets our patient’s needs with extended hours. Day, night, and weekend appointments are available. Our Nurse Practitioners follow the National Infusion Center Association guidelines and our proprietary clinical protocols. Sage Infusion offers a variety of comforting amenities, and patients can choose to receive treatment in the open lounge or a private room. From a quick start to upfront pricing and financial assistance to compassionate care by our clinical experts in a serene environment, you will experience infusion therapy like never before. Sage Infusion offers the best infusion and administration facilities in the Sunshine State with eleven locations – Brandon, Clearwater, Lakeland, St. Pete, Fort Myers, Orlando, Sarasota, Tampa, The Villages Lake Sumter, Ocala, and The Villages Spanish Springs.